Business context and reporting period
The supplied filing is IsoRay, Inc.’s Form 10-Q for the quarter ended September 30, 2016, filed November 9, 2016. This does not match the request metadata identifying Perspective Therapeutics or “2016 Q1”; the summary below reflects the filing text.
IsoRay manufactures and sells Cesium-131 brachytherapy seeds for cancer treatment. It reported no revenue from its distributors in Italy and Russia during the quarter.
Financial results and liquidity
Amounts below are in thousands of dollars, except per-share data and percentages.
| Metric | Quarter ended Sep. 30, 2016 | Prior-year quarter | Change |
|---|---|---|---|
| Product sales, net | $1,081 | $1,261 | Down 14% |
| Gross profit (margin) | $48 (4%) | $83 (7%) | Down 42% |
| Operating expenses | $1,623 | $1,174 | Up 38% |
| Operating loss | $(1,575) | $(1,091) | Loss widened 44% |
| Net loss | $(1,498) | $(1,020) | Loss widened 47% |
| Net loss per share | $(0.03) | $(0.02) | |
| Operating cash used | $(1,353) | $(1,109) |
At September 30, cash and cash equivalents were $8.459 million, with current certificates of deposit of $5.249 million; total cash and current CDs were $13.708 million. Working capital was $13.801 million and the current ratio was 13.28. Total liabilities were $1.712 million, including a $588,000 asset retirement obligation; the balance sheet shows no conventional debt. Cash declined $1.680 million during the quarter. Investing cash use was $327,000, primarily for equipment, other assets, and certificates of deposit; there was no financing cash flow.
Material changes versus the prior comparable period
- Sales fell by $180,000. Prostate brachytherapy sales declined 13%, while other brachytherapy sales declined 21%.
- Gross margin contracted to about 4% from 7%, as cost of product sales declined less than revenue.
- Sales and marketing expense rose 88%, reflecting rebranding, website redesign, and added sales and marketing positions. General and administrative expense rose 23%, partly due to new hires and public-company costs.
- Research and development expense increased 19%, with increased intellectual-property maintenance legal costs cited.
- Cash used in operations increased from $1.109 million to $1.353 million.
Outlook, commentary, risks, and unusual items
- Management forecast that current cash and certificates of deposit would cover projected operating needs for fiscal 2017, assuming no extraordinary expenses. It targeted 20% fiscal 2017 revenue growth and said cash-flow break-even might be reached in three to five years if growth targets were achieved; neither outcome was assured.
- Management expected to invest approximately $390,000 more in fiscal 2017 to automate production processes. It was also designing a future production and administration facility, contingent on obtaining financing.
- The company said future funding could come from equity, strategic collaborations, debt, or other sources, and warned that additional financing could be dilutive and priced at a discount.
- Five customers accounted for approximately 48% of quarterly revenue, with nearly 22% from one customer. Management warned that losing a major customer could materially harm revenue.
- A securities class action related to a 2015 press release had a proposed $3.538 million settlement payable by insurers. The court granted preliminary approval; final approval was pending, with a hearing scheduled for March 7, 2017. A separate shareholder derivative action sought unspecified relief; the company noted possible advancement of defense costs and applicable D&O insurance.
- Quarterly other income included approximately $16,000 in vendor-audit refunds and a $5,000 gain on asset disposals. A $27,000 favorable change in warrant derivative fair value was also recorded; the derivative liability was zero at quarter-end.
- Disclosure controls were assessed as effective, and management reported no material change in internal control over financial reporting.
Important facts for investors to verify
- Confirm the filing entity and period: the source is IsoRay, Inc., quarter ended September 30, 2016, not the company and period in the request metadata.
- Track revenue trends, customer concentration, and whether the stated 20% fiscal 2017 growth target is achieved.
- Monitor cash use, available liquidity, planned automation spending, facility financing, and any need for potentially dilutive capital.
- Check final court approval and insurer payment of the proposed class-action settlement, and developments in the derivative action.
- Assess whether the production automation investment improves capacity, costs, and gross margins as management expects.